BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25143337)

  • 1. Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis.
    Akçali C; Guven EH; Kirtak N; Inaloz HS; Ozgoztasi O; Guvenc U
    J Int Med Res; 2014 Oct; 42(5):1118-22. PubMed ID: 25143337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
    Engin B; Tanakol A; Bulut H; Songür A; Vehid HE; Gökalp E; Kutlubay Z; Özkoca D; Tüzün Y; Serdaroğlu S
    Int J Dermatol; 2020 Feb; 59(2):207-215. PubMed ID: 31531981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study.
    Dogra S; Jain A; Kanwar AJ
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e305-11. PubMed ID: 22816881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis.
    Mussi A; Bonifati C; Carducci M; D'Agosto G; Pimpinelli F; D'Urso D; D'Auria L; Fazio M; Ameglio F
    J Biol Regul Homeost Agents; 1997; 11(3):115-8. PubMed ID: 9498161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial.
    Caproni M; Antiga E; Melani L; Volpi W; Del Bianco E; Fabbri P
    J Clin Immunol; 2009 Mar; 29(2):210-4. PubMed ID: 18763027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab (Cosentyx°) and plaque psoriasis.
    Prescrire Int; 2017 Mar; 26(180):61-62. PubMed ID: 30730616
    [No Abstract]   [Full Text] [Related]  

  • 7. HLA-G 14-bp polymorphism: a possible marker of systemic treatment response in psoriasis vulgaris? Preliminary results of a retrospective study.
    Borghi A; Rizzo R; Corazza M; Bertoldi AM; Bortolotti D; Sturabotti G; Virgili A; Di Luca D
    Dermatol Ther; 2014; 27(5):284-9. PubMed ID: 24909182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythroderma in a patient taking acitretin for plaque psoriasis.
    Ahdout J; Mandel H; Chiu M
    J Drugs Dermatol; 2008 Apr; 7(4):391-4. PubMed ID: 18459522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis.
    Kuijpers AL; van Dooren-Greebe JV; van de Kerkhof PC
    Dermatology; 1997; 194(1):88-90. PubMed ID: 9031805
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris.
    Antiga E; Volpi W; Chiarini C; Cardilicchia E; Filì L; Manuelli C; Parrochi P; Fabbri P; Caproni M
    Int J Immunopathol Pharmacol; 2010; 23(3):767-74. PubMed ID: 20943046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis.
    Ikonomidis I; Papadavid E; Makavos G; Andreadou I; Varoudi M; Gravanis K; Theodoropoulos K; Pavlidis G; Triantafyllidi H; Moutsatsou P; Panagiotou C; Parissis J; Iliodromitis E; Lekakis J; Rigopoulos D
    Circ Cardiovasc Imaging; 2017 Sep; 10(9):. PubMed ID: 28899951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of acitretin and commercial tanning bed therapy for psoriasis.
    Carlin CS; Callis KP; Krueger GG
    Arch Dermatol; 2003 Apr; 139(4):436-42. PubMed ID: 12707089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin nanoparticles potentiate therapeutic effectiveness of acitrein in moderate-to-severe psoriasis patients and control serum cholesterol levels.
    Bilia AR; Bergonzi MC; Isacchi B; Antiga E; Caproni M
    J Pharm Pharmacol; 2018 Jul; 70(7):919-928. PubMed ID: 29600580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study.
    Janagond AB; Kanwar AJ; Handa S
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e384-9. PubMed ID: 23066720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential therapy using cyclosporine and acitretin for treatment of total body psoriasis.
    Short MW; Vaughan TK
    Cutis; 2004 Sep; 74(3):185-8. PubMed ID: 15499760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis.
    Ozdemir M; Engin B; Baysal I; Mevlitoğlu I
    Acta Derm Venereol; 2008; 88(6):589-93. PubMed ID: 19002344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial.
    Yu C; Fan X; Li Z; Liu X; Wang G
    Eur J Dermatol; 2017 Apr; 27(2):150-154. PubMed ID: 28400341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P; Del Giglio M; Cotena C; Girolomoni G
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.